



Biotech Daily

Friday October 21, 2016

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH UP: ORTHOCELL UP 10%; ACTINOGEN DOWN 6%**
- * **CLEVELAND OKAYS RESAPP US PAEDIATRIC RESPIRATORY TRIAL**
- * **IMUGENE RAISES \$3.2m**
- * **VIRALYTICS AGM FOR 666k DIRECTOR OPTIONS**
- * **FACTOR THERAPEUTICS 1m DR ROBERT RYAN OPTIONS AGM**
- * **GENERA 1m CEO RICHARD HANNEBERY 'RIGHTS', 250k OPTION AGM**
- * **BOTANIX 16m DIRECTOR OPTIONS AGM**
- * **RESPIRI 10m DIRECTOR OPTIONS AGM; DIRECTORS GO**
- * **DEUTSCHE BANK TAKES 14% OF GENETIC SIGNATURES**
- * **BRENDAN MORAN TAKES PROFIT TO BELOW 5% OF LBT**

MARKET REPORT

The Australian stock market fell 0.22 percent on Friday October 21, 2016 with the ASX200 down 11.8 points to 5,430.3 points. Seventeen of the Biotech Daily Top 40 stocks were up, 13 fell, seven traded unchanged and three were untraded. All three Big Caps fell.

Orthocell was the best, up 4.5 cents or 10.1 percent to 49 cents with 690,226 shares traded.

Avita climbed 8.3 percent; Compumedics was up 6.5 percent; Pro Medicus improved 5.7 percent; Benitec, IDT and Prana were up more than four percent; Ellex, Medical Developments and Starpharma rose more than two percent; Bionomics, Clinuvel, Factor Therapeutics and Viralytics were up more than one percent; with Cyclopharm, Impedimed and Mesoblast up by less than one percent.

Actinogen led the falls, down 0.3 cents or 6.1 percent to 4.6 cents with 160,000 shares traded.

Oncosil and Polynovo fell more than four percent; Admedus lost 3.5 percent; Neuren and Universal Biosensors shed more than two percent; Acrux, Anteo, Cochlear, CSL, Nanosonics and Osprey were down more than one percent; with Airxpanders, Genetic Signatures, Resmed and Sirtex down by less than one percent.

RESAPP HEALTH

Resapp says it has its first institutional review board approval to evaluate the Resappdx software diagnosis of childhood respiratory conditions from cough sounds.

Resapp said that the Ohio-based Cleveland Clinic was the first to approve patient enrolment in the Smartcough-C prospective, multi-site, double blind study at three US hospitals.

The company said that the primary endpoints for the study would be the diagnosis of pneumonia with secondary endpoints the diagnosis of other common childhood respiratory diseases such as upper respiratory tract infection, croup, bronchiolitis and asthma.

Resapp said that respiratory disease diagnosis was based on a combination of auscultation, imaging and laboratory tests and an instant, accurate diagnostic test delivered through an internet connected mobile telephone "could greatly improve patient management, give greater access to healthcare and reduce costs".

The company said that pneumonia was the leading cause of death of children under five years of age, globally, and the most common reason for US children to be hospitalized.

Resapp said that Cleveland Clinic's centre for paediatric pulmonary medicine director Dr John Carl would be the Clinic's principal investigator.

Resapp was up 2.5 cents or 5.3 percent to 49.5 cents with 3.9 million shares traded.

IMUGENE

Imugene says it has raised \$3.2 million in a placement at 0.75 cents a share to institutional investors as well as new and existing sophisticated investors.

Imugene said that the funds would support its phase Ib gastric cancer trial in Taiwan, Hong Kong and Thailand and provide general working capital.

The company said that the lead manager was the London-based WG Partners LP.

Imugene was up 0.1 cents or 12.5 percent to 0.9 cents with 40.6 million shares traded.

VIRALYTICS

Viralytics will vote to grant 666,000 options to chairman Paul Hopper and directors Dr Leonard Post and Peter Turvey.

Viralytics said that the options would vest in three tranches over three years from issue and be exercisable within five years at the 5-day volume-weighted average price to the date of the annual general meeting.

Last year, Viralytics shareholders overwhelmingly approved the issue of 300,000 options for Mr Hopper and 200,000 options each to Mr Turvey and Dr Post with about 3.5 million votes against the options and 65.6 million votes in favor (BD: Oct 19, 2015).

In 2014, 19.5 percent of Viralytics voting shareholders opposed the grant of 400,000 options each to chief executive officer Dr Malcolm McColl and Mr Turvey and 200,000 options each to Mr Hopper and Dr Len Post, with 21.0 percent opposing the remuneration report (BD: Oct 24, Nov 27, 2014).

Today, the company's notice of meeting said shareholders would vote on the re-election of Mr Turvey, the remuneration report, approval of the equity incentive plan, the ratification of placement shares at 61.5 cents a share and renewing the 10 percent placement capacity.

The meeting will be held at McCullough Robertson, Level 32, MLC Centre, 19-29 Martin Place, Sydney on November 23, 2016 at 11am (AEDT).

Viralytics was up 1.5 cents or 1.2 percent to \$1.24.

FACTOR THERAPEUTICS

Factor Therapeutics will vote to grant 1,000,000 options to director Dr Robert Ryan exercisable at 11 cents each within five years.

Factor Therapeutics said the options would vest in three tranches with 500,000 vesting on shareholder approval with 250,000 options vesting 12 months and 24 months after issue.

The company said that excluding the value of the options, Dr Ryan received \$US65,00 a year for his role as a non-executive director.

Last year, the then Tissue Therapies, voted to grant 1,600,000 options to executive director Dr Christian Behrenbruch, chairman Dr Cherrell Hirst and Tim Hughes in partial lieu of pay (BD: Oct 27, 2015).

Today, Factor Therapeutics said that the annual general meeting would vote on the remuneration report, the re-election of directors Tim Hughes and Dr Ryan, a new constitution and approval of an additional capacity to issue shares.

The meeting will be held at the offices of McCullough Robertson, Level 11 Central Plaza Two, 66 Eagle Street, Brisbane on November 23, 2016 at 9.30am (AEST).

Factor Therapeutics was up 0.1 cents or 1.45 percent to seven cents.

GENERA BIOSYSTEMS

Genera will vote to grant chief executive officer Richard Hannebery 1,000,000 "performance rights" and 250,000 options.

Genera said Mr Hannebery was paid \$180,000 a year as chief executive officer and 50 percent of the free performance rights would vest pending the achievement of key performance indicators and the balance pending a total shareholder return measure, with the 250,000 options exercisable at 30 cents each by December 30, 2016.

Last year, the Genera annual general meeting approved overwhelmingly 2,000,000 'performance rights' for Mr Hannebery (BD: Oct 27, 2015).

The Genera notice of annual general meeting said the meeting would vote on remuneration report, the re-election of directors Dr Karl Poetter and James Kalokerinos, the approval of the issue of 3,916,667 options under the mezzanine loan financing facility and the approval of the 10 percent placement capacity.

The meeting will be held at Grant Thornton, Level 30, The Rialto, 525 Collins Street, Melbourne on November 24, 2016 at 11.30am (AEDT).

Genera was unchanged at 22 cents.

BOTANIX PHARMACEUTICALS

Botanix will vote to grant chairman Robert Towner and directors Graham Griffiths, and Dr William Bosch 16,215,959 options.

Botanix said that the options would vest in three annual installments, exercisable at a 50 percent premium to the closing price before the annual general meeting and expiring three years from the issue date, with Dr Bosch receiving 8,107,979 options and Mr Griffiths and Mr Towner receiving 4,053,990 options each.

The company said that Mr Griffiths and Mr Towner were paid \$50,000 each a year in directors fees with Dr Bosch receiving \$US100,000 (\$A131,857) a year.

Botanix said that shareholders would vote on the remuneration report, the re-election of Mr Towner and approval of the 10 percent placement capacity,

The meeting will be held at CWA House, 1176 Hay Street West, Western Australia, on November 30, 2016 at 2pm (AWST).

Botanix fell 0.1 cents or two percent to 4.8 cents.

[RESPIRI \(FORMERLY ISONEA, PREVIOUSLY KARMELSONIX\)](#)

Respiri will vote to grant directors 10,000,000 options exercisable at 28.5 cents each by November 30, 2019 and ratify the issue of 6,666,667 shares to the CFO Solution.

Respiri's notice of meeting said that directors David Ashmore and Mr Ross Blair-Holt, who were appointed in 2014, would retire from the board at the date of the meeting.

Respiri said that shareholders would vote to issue 4,000,000 options to chairman Leon L'Huillier, with 2,000,000 options each to directors John Ribot-de-Bresac and Dr Timothy Oldham, as well as 2,000,000 options for the Wall Partnership Pty Ltd.

The company said that shareholders would vote to approve the prior issue of 6,666,667 shares at three cents each, worth \$200,000, to the CFO Solution of High Street, Armadale, Victoria in lieu of cash payment for accounting and secretarial services.

Respiri's notice of meeting said shareholders would vote on the remuneration report, the 10 percent placement capacity and the re-election of director Mr Ribot-de-Bresac.

The meeting will be held at Giorgios Restaurant Function Room, 1235 High Street, Armadale on November 22, 2016 at 4.30pm (AEDT).

Respiri was up 0.2 cents or 3.45 percent to six cents.

[GENETIC SIGNATURES](#)

Deutsche Bank and related bodies corporate say they have become substantial shareholders in Genetic Signatures with 14,893,618 shares (14.24%).

The Hong Kong and Sydney based Deutsche Bank AG said that it acquired all the shares on October 19, 2016 at 47 cents a share and the registered holder was Pan Australian Nominees.

Genetic Signatures fell half a cent or 0.9 percent to 54 cents.

[LBT INNOVATIONS](#)

Brendan Moran says he has sold 1,760,000 LBT shares for \$1,147,125 or 65.2 cents a shares reducing his holding to 5,754,726 shares (4.90%)

Last week, LBT climbed 357.9 percent from 19 cents to 87 cents following US Food and Drug Administration approval of its automated plate assessment system (APAS) (BD: Oct 10, 13, 2016).

Last year, the Sydney-based Mr Moran said he increased his holding in LBT with the largest single purchase 199,714 shares at 7.0 cents a share (BD: Jul 31, 2015).

LBT fell one cent or 1.5 percent to 67 cents with 3.2 million shares traded.